Gao H R
Cancer Hospital, Shanghoi University of Medical Sciences.
Zhonghua Zhong Liu Za Zhi. 1989 May;11(3):204-6.
Mitoxantrone prepared by Shanghai Institute of Pharmaceutical Industry is reported. 154 patients with various advanced cancers confirmed by pathology were treated by mitoxantrone with a dose of 14 mg/M2, i. v., once every 3 or 4 weeks from Feb. 1985 to Feb. 1987. There were 96 males and 58 females. The ages ranged from 16 to 76 years with an mean age of 48 +/- 15. Objective response rates were 21% in breast cancer, 36% in non-Hodgkin's lymphoma, 56% in acute lymphocytic leukemia, 14% in acute nonlymphocytic leukemia, 31% in gastric cancer and 5% in primary hepatic cancer. The side effects were leukopenia and gastro-intestinal disturbances. No marked cardiac toxicity was observed.
报道了上海医药工业研究院制备的米托蒽醌。1985年2月至1987年2月，对154例经病理确诊的各种晚期癌症患者采用米托蒽醌治疗，剂量为14mg/M²，静脉注射，每3或4周1次。其中男性96例，女性58例。年龄范围为16至76岁，平均年龄48±15岁。客观缓解率在乳腺癌中为21%，在非霍奇金淋巴瘤中为36%，在急性淋巴细胞白血病中为56%，在急性非淋巴细胞白血病中为14%，在胃癌中为31%，在原发性肝癌中为5%。副作用为白细胞减少和胃肠道紊乱。未观察到明显的心脏毒性。
